A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease
Background. To investigate whether PPIs BID is superior to QD for treatment of GERD in a short time. Methods. We searched PubMed, Cochrane Library, Scopus, EMBASE, Ovid, EBSCO, and Web of Science databases (from 1998 to May 2016) to select RCTs, which compared the efficacy of PPIs BID versus QD for...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/9865963 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556127141756928 |
|---|---|
| author | Hongying Zhang Zhiping Yang Zhen Ni Yongquan Shi |
| author_facet | Hongying Zhang Zhiping Yang Zhen Ni Yongquan Shi |
| author_sort | Hongying Zhang |
| collection | DOAJ |
| description | Background. To investigate whether PPIs BID is superior to QD for treatment of GERD in a short time. Methods. We searched PubMed, Cochrane Library, Scopus, EMBASE, Ovid, EBSCO, and Web of Science databases (from 1998 to May 2016) to select RCTs, which compared the efficacy of PPIs BID versus QD for GERD. The primary outcomes were symptom relief or esophageal mucosal healing at weeks 4 and 8. The M-H method with fixed-effect or random-effect model was used to calculate RR and 95% CIs. Results. Seven RCTs were enrolled. The esophageal healing rates were higher in PPIs BID group (P=0.01), and rabeprazole 20 mg BID can achieve better mucosal healing than 20 mg QD after 8 weeks (P<0.05). However, no significant differences were observed in heartburn relief (P=0.27), sustained symptom relief rates at week 4 (P=0.05), 24 h pH monitoring after treatment (P=0.11), endoscopic response at week 4 (P=0.22), and adverse events (P=0.18). Conclusion. PPIs BID more effectively improve endoscopic healing rate at week 8 than PPIs QD. But there are no significant differences in symptom relief, 24 h pH monitoring, sustained symptom relief, and endoscopic response at week 4. |
| format | Article |
| id | doaj-art-d48916f53dea4d3aa57cf073824c0189 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-d48916f53dea4d3aa57cf073824c01892025-02-03T05:46:18ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/98659639865963A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux DiseaseHongying Zhang0Zhiping Yang1Zhen Ni2Yongquan Shi3State Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaState Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaState Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaState Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, ChinaBackground. To investigate whether PPIs BID is superior to QD for treatment of GERD in a short time. Methods. We searched PubMed, Cochrane Library, Scopus, EMBASE, Ovid, EBSCO, and Web of Science databases (from 1998 to May 2016) to select RCTs, which compared the efficacy of PPIs BID versus QD for GERD. The primary outcomes were symptom relief or esophageal mucosal healing at weeks 4 and 8. The M-H method with fixed-effect or random-effect model was used to calculate RR and 95% CIs. Results. Seven RCTs were enrolled. The esophageal healing rates were higher in PPIs BID group (P=0.01), and rabeprazole 20 mg BID can achieve better mucosal healing than 20 mg QD after 8 weeks (P<0.05). However, no significant differences were observed in heartburn relief (P=0.27), sustained symptom relief rates at week 4 (P=0.05), 24 h pH monitoring after treatment (P=0.11), endoscopic response at week 4 (P=0.22), and adverse events (P=0.18). Conclusion. PPIs BID more effectively improve endoscopic healing rate at week 8 than PPIs QD. But there are no significant differences in symptom relief, 24 h pH monitoring, sustained symptom relief, and endoscopic response at week 4.http://dx.doi.org/10.1155/2017/9865963 |
| spellingShingle | Hongying Zhang Zhiping Yang Zhen Ni Yongquan Shi A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease Gastroenterology Research and Practice |
| title | A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease |
| title_full | A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease |
| title_fullStr | A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease |
| title_full_unstemmed | A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease |
| title_short | A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease |
| title_sort | meta analysis and systematic review of the efficacy of twice daily ppis versus once daily for treatment of gastroesophageal reflux disease |
| url | http://dx.doi.org/10.1155/2017/9865963 |
| work_keys_str_mv | AT hongyingzhang ametaanalysisandsystematicreviewoftheefficacyoftwicedailyppisversusoncedailyfortreatmentofgastroesophagealrefluxdisease AT zhipingyang ametaanalysisandsystematicreviewoftheefficacyoftwicedailyppisversusoncedailyfortreatmentofgastroesophagealrefluxdisease AT zhenni ametaanalysisandsystematicreviewoftheefficacyoftwicedailyppisversusoncedailyfortreatmentofgastroesophagealrefluxdisease AT yongquanshi ametaanalysisandsystematicreviewoftheefficacyoftwicedailyppisversusoncedailyfortreatmentofgastroesophagealrefluxdisease AT hongyingzhang metaanalysisandsystematicreviewoftheefficacyoftwicedailyppisversusoncedailyfortreatmentofgastroesophagealrefluxdisease AT zhipingyang metaanalysisandsystematicreviewoftheefficacyoftwicedailyppisversusoncedailyfortreatmentofgastroesophagealrefluxdisease AT zhenni metaanalysisandsystematicreviewoftheefficacyoftwicedailyppisversusoncedailyfortreatmentofgastroesophagealrefluxdisease AT yongquanshi metaanalysisandsystematicreviewoftheefficacyoftwicedailyppisversusoncedailyfortreatmentofgastroesophagealrefluxdisease |